New Views of a Cough: From TB to Hope for Parkinson's New Views of a Cough: From TB to Hope for Parkinson's
Scientists are revealing new secrets of the reflex that protects our lungs, spreads disease, and irritates us all.Knowable Magazine (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 29, 2023 Category: Internal Medicine Tags: Internal Medicine News Source Type: news
Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review
MILAN, June 29, 2023--(BUSINESS WIRE)--Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for Givinostat. Givinostat is the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 29, 2023 Category: Drugs & Pharmacology Source Type: news
Central Ohio's growing biotech industry celebrates Nationwide Children's gene therapy win
The FDA's approval of a gene therapy invented at Nationwide Children's Hospital for an aggressive form of muscular dystrophy was cause for celebration not only there but at ostensible competitors in a growing Central Ohio biotech industry. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 26, 2023 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news
Obama Issues'Russia-Sympathetic' Words In CNN Interview
Obama Issues 'Russia-Sympathetic' Words In CNN Interview Former US President Barack Obama issued some surprising statements related to the Russia-Ukraine war, which came during a CNN interview which aired Thursday. Any other celebrated mainstream political commentator might have been canceled over…#obamaissues #barackobama #amanpour #ukraine #christianeamanpour #crimea #russian #angelamerkel #europeans #kremlin (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2023 Category: Consumer Health News Source Type: news
FDA Approves Gene Therapy for Rare Muscular Dystrophy FDA Approves Gene Therapy for Rare Muscular Dystrophy
The health regulator has granted accelerated approval to Sarepta Therapeutics ' first-of-its-kind gene therapy for Duchenne muscular dystrophy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
FDA Approves First Gene Therapy to Treat Duchenne Muscular Dystrophy
FRIDAY, June 23, 2023 -- The U.S. Food and Drug Administration on Thursday approved the drug Elevidys, the first gene therapy for the treatment of children with Duchenne muscular dystrophy (DMD).
The groundbreaking treatment will not be cheap:... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 23, 2023 Category: General Medicine Source Type: news
FDA Approves First Gene Therapy, Elevidys, to Treat Duchenne Muscular Dystrophy
FRIDAY, June 23, 2023 -- The U.S. Food and Drug Administration on Thursday approved the drug Elevidys, the first gene therapy for the treatment of children with Duchenne muscular dystrophy (DMD).
The groundbreaking treatment will not be cheap:... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 23, 2023 Category: General Medicine Source Type: news
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Dear Investor,Please find attached a press release from our partner Sarepta Therapeutics:https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-geneFor further information please also have a look at the attached Roche statement on the accelerated approval of Elevidys™ granted by the FDA.Do not hesitate to contact us for any further questions.With best regards,Roche Investor Relations Dr. Bruno EschliPhone: +41 61 68-75284e-mail:bruno.eschli@roche.com Dr. Sabine Borngr äberPhone: +41 61 68-88027e-mail:sabine.borngraeber@roche.com ...
Source: Roche Investor Update - June 23, 2023 Category: Pharmaceuticals Source Type: news
The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million
The Food and Drug Administration approved the therapy for Duchenne muscular dystrophy, following a fast-track review. Young children with Duchenne muscular dystrophy can now get the first gene therapy for the crippling muscle condition. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2023 Category: Consumer Health News Source Type: news
FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy
For genetic conditions like Duchenne muscular dystrophy, there is little doctors can do to slow or treat the condition other than trying to manage symptoms, since only addressing the genetic changes responsible can help halt the disease.
Earlier today (June 22), the U.S. Food and Drug Administration (FDA) approved the first such intervention, a gene therapy called Elevidys, from Sarepta Therapeutics, a Massachusetts-based biotech company. The approval applies only to children ages 4 and 5, which reflects the conflicting opinions within the agency about the quality of data supporting the gene therapy’s effectiveness, ...
Source: TIME: Health - June 23, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Genetics healthscienceclimate Source Type: news
1st gene therapy for deadly form of muscular dystrophy gets FDA approval for kids
The U.S. Food and Drug Administration has approved the first gene therapy to treat a deadly form of muscular dystrophy (Source: ABC News: Health)
Source: ABC News: Health - June 22, 2023 Category: Consumer Health News Tags: Health Source Type: news
FDA Approves Elevidys (delandistrogene moxeparvovec-rokl) Gene Therapy to Treat Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 22, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of Elevidys... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 22, 2023 Category: Drugs & Pharmacology Source Type: news
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids
The U.S. Food and Drug Administration has approved the first gene therapy to treat a deadly form of muscular dystrophy. (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2023 Category: Consumer Health News Source Type: news
Sarepta to price new Duchenne gene therapy at $3.2M
The Cambridge drugmaker's newly approved gene therapy for Duchenne muscular dystrophy is a one-time treatment. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 22, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young children
The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment’s ability to help boys with the inherited disease. The Food and Drug Administration approval provides a new option for…#fda #sareptatherapeutics #iv #petermarks #lougehrigs #duchenne #cambridge #massachusetts #sarepta #pfizer (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2023 Category: Consumer Health News Source Type: news
